EXE vs. WELL, DR, SIA, DNTL, GUD, ACB, FRX, WEED, KSI, and VHI
Should you be buying Extendicare stock or one of its competitors? The main competitors of Extendicare include WELL Health Technologies (WELL), Medical Facilities (DR), Sienna Senior Living (SIA), dentalcorp (DNTL), Knight Therapeutics (GUD), Aurora Cannabis (ACB), Fennec Pharmaceuticals (FRX), Canopy Growth (WEED), kneat.com (KSI), and Vitalhub (VHI). These companies are all part of the "medical" sector.
WELL Health Technologies (TSE:WELL) and Extendicare (TSE:EXE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation, institutional ownership and community ranking.
4.8% of WELL Health Technologies shares are held by institutional investors. Comparatively, 21.2% of Extendicare shares are held by institutional investors. 9.6% of WELL Health Technologies shares are held by company insiders. Comparatively, 13.6% of Extendicare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, WELL Health Technologies had 5 more articles in the media than Extendicare. MarketBeat recorded 5 mentions for WELL Health Technologies and 0 mentions for Extendicare. Extendicare's average media sentiment score of 0.28 beat WELL Health Technologies' score of 0.00 indicating that WELL Health Technologies is being referred to more favorably in the media.
WELL Health Technologies has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Extendicare has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500.
Extendicare received 112 more outperform votes than WELL Health Technologies when rated by MarketBeat users. However, 66.10% of users gave WELL Health Technologies an outperform vote while only 49.19% of users gave Extendicare an outperform vote.
Extendicare has higher revenue and earnings than WELL Health Technologies.
WELL Health Technologies currently has a consensus target price of C$7.25, suggesting a potential upside of 101.95%. Extendicare has a consensus target price of C$7.88, suggesting a potential upside of 7.88%. Given Extendicare's stronger consensus rating and higher probable upside, equities research analysts clearly believe WELL Health Technologies is more favorable than Extendicare.
Extendicare has a net margin of 2.60% compared to Extendicare's net margin of 0.01%. WELL Health Technologies' return on equity of 36.03% beat Extendicare's return on equity.
Summary
Extendicare beats WELL Health Technologies on 9 of the 17 factors compared between the two stocks.
Get Extendicare News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EXE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Extendicare Competitors List
Related Companies and Tools
